Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease
Authors:
- Magdalena Sobieraj-TeagueMSMagdalena Sobieraj-Teague
- Jack HirshJHJack Hirsh
- Martin O'DOnnellMOMartin O'DOnnell
- John EikelboomJEJohn Eikelboom
- 1 July 2011
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 124 (7) , 621-629
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Aspirin Intake and Survival After Breast CancerJournal of Clinical Oncology, 2010
- Aspirin Use and Survival After Diagnosis of Colorectal CancerJAMA, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statinsTrials, 2007
- Meta-Analysis of Data from the Six Primary Prevention Trials of Cardiovascular Events Using AspirinThe American Journal of Cardiology, 2006
- Low-Dose Aspirin for Primary Prevention of Cardiovascular DiseaseSeminars in Vascular Medicine, 2003
- Rationale for a Trial of Low-Dose Aspirin for the Primary Prevention of Major Adverse Cardiovascular Events and Vascular Dementia in the ElderlyDrugs & Aging, 2003
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Global Burden of Cardiovascular DiseasesCirculation, 2001
- Randomised trial of prophylactic daily aspirin in British male doctorsBMJ, 1988